Skip to main content
Top
Published in: CEN Case Reports 1/2023

04-08-2022 | IgA Vasculitis | Case Report

IgA vasculitis with transient glomerular hematuria, diarrhea, and pericarditis following COVID-19 mRNA vaccination in a young patient with possible pre-existing ulcerative colitis

Authors: Chiaki Ito, Kohei Odajima, Yoshiko Niimura, Misako Fujii, Masayuki Sone, Shinichiro Asakawa, Shigeyuki Arai, Osamu Yamazaki, Yoshifuru Tamura, Koji Saito, Yayoi Tada, Takatsugu Yamamoto, Ken Kozuma, Shigeru Shibata, Yoshihide Fujigaki

Published in: CEN Case Reports | Issue 1/2023

Login to get access

Abstract

Exacerbations or de novo autoimmune/autoinflammatory disease have been reported after COVID-19 vaccination. A young male presented with cutaneous IgA vasculitis with glomerular hematuria, diarrhea and pericarditis following his second COVID-19 mRNA vaccination. He also showed positivity for proteinase 3 anti-neutrophil cytoplasmic antibody (PR3-ANCA) and anti-cardiolipin antibody. Skin biopsy was compatible to IgA vasculitis. His purpura subsided and hematuria spontaneously disappeared. Treatment with anti-inflammatory medications and prednisolone resolved the pericarditis. He had a history of persistent diarrhea, and colonic biopsies showed possible ulcerative colitis without vasculitis. Kidney biopsy after prednisolone therapy revealed minor glomerular abnormalities without any immune reactants and did not show vasculitis. After prednisolone treatment, PR3-ANCA decreased in a medium degree despite of improvement of symptoms and inflammatory data, suggesting that his PR3-ANCA may be associated with ulcerative colitis. The cause of the transient glomerular hematuria was unclear, however, it might be caused by focal glomerular active lesions (glomerular vasculitis) due to vaccine-induced IgA vasculitis with nephritis. This case highlights that COVID-19 mRNA vaccination can activate multiple autoimmune/autoinflammatory systems. The conditions might help us better understand the mutual mechanisms of the relevant disorders.
Literature
1.
go back to reference Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med. 2009;360:1981–8.CrossRef Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med. 2009;360:1981–8.CrossRef
2.
go back to reference Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME, Brodavka M, Cohen Y, Abu-Much A, Abu Elhija M, Bridgewood C, Langevitz P, McLorinan J, Bragazzi NL, Marzo-Ortega H, Lidar M, Calabrese C, Calabrese L, Vital E, Shoenfeld Y, Amital H, McGonagle D. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines (Basel). 2021;9:435.CrossRef Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME, Brodavka M, Cohen Y, Abu-Much A, Abu Elhija M, Bridgewood C, Langevitz P, McLorinan J, Bragazzi NL, Marzo-Ortega H, Lidar M, Calabrese C, Calabrese L, Vital E, Shoenfeld Y, Amital H, McGonagle D. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines (Basel). 2021;9:435.CrossRef
3.
go back to reference Chan ATP, Tang SCW. De novo and relapsing glomerulonephritis after COVID-19 vaccination: how much do we know? Nephrology (Carlton). 2022;27:5–6.CrossRef Chan ATP, Tang SCW. De novo and relapsing glomerulonephritis after COVID-19 vaccination: how much do we know? Nephrology (Carlton). 2022;27:5–6.CrossRef
4.
go back to reference Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2021;11: 617089.CrossRef Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2021;11: 617089.CrossRef
5.
go back to reference Hines AM, Murphy N, Mullin C, Barillas J, Barrientos JC. Henoch-Schönlein purpura presenting post-COVID-19 vaccination. Vaccine. 2021;39:4571–2.CrossRef Hines AM, Murphy N, Mullin C, Barillas J, Barrientos JC. Henoch-Schönlein purpura presenting post-COVID-19 vaccination. Vaccine. 2021;39:4571–2.CrossRef
6.
go back to reference Naitlho A, Lahlou W, Bourial A, Rais H, Ismaili N, Abousahfa I, Belyamani L. A rare case of Henoch-Schönlein purpura following a COVID-19 vaccine-case report. SN Compr Clin Med. 2021;8:1–4. Naitlho A, Lahlou W, Bourial A, Rais H, Ismaili N, Abousahfa I, Belyamani L. A rare case of Henoch-Schönlein purpura following a COVID-19 vaccine-case report. SN Compr Clin Med. 2021;8:1–4.
7.
go back to reference Sirufo MM, Raggiunti M, Magnanimi LM, Ginaldi L, De Martinis M. Henoch Schönlein purpura following the first dose of COVID-19 viral vector vaccine: a case report. Vaccines (Basel). 2021;9:1078.CrossRef Sirufo MM, Raggiunti M, Magnanimi LM, Ginaldi L, De Martinis M. Henoch Schönlein purpura following the first dose of COVID-19 viral vector vaccine: a case report. Vaccines (Basel). 2021;9:1078.CrossRef
8.
go back to reference Obeid M, Fenwick C, Pantaleo G. Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatol. 2021;3: e617.CrossRef Obeid M, Fenwick C, Pantaleo G. Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatol. 2021;3: e617.CrossRef
9.
go back to reference Kondo M, Yamanaka K. Possible HSP reactivation post-COVID-19 vaccination and booster. Clin Case Rep. 2021;9: e05032.CrossRef Kondo M, Yamanaka K. Possible HSP reactivation post-COVID-19 vaccination and booster. Clin Case Rep. 2021;9: e05032.CrossRef
10.
go back to reference Mohamed MMB, Wickman TJ, Fogo AB, Velez JCQ. De novo immunoglobulin a vasculitis following exposure to SARS-CoV-2 immunization. Ochsner J. 2021;21:395–401.CrossRef Mohamed MMB, Wickman TJ, Fogo AB, Velez JCQ. De novo immunoglobulin a vasculitis following exposure to SARS-CoV-2 immunization. Ochsner J. 2021;21:395–401.CrossRef
11.
go back to reference Badier L, Toledano A, Porel T, Dumond S, Jouglen J, Sailler L, Bagheri H, Moulis G, Lafaurie M. IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19. Autoimmun Rev. 2021;20: 102951.CrossRef Badier L, Toledano A, Porel T, Dumond S, Jouglen J, Sailler L, Bagheri H, Moulis G, Lafaurie M. IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19. Autoimmun Rev. 2021;20: 102951.CrossRef
12.
go back to reference Maye JA, Chong HP, Rajagopal V, Petchey W. Reactivation of IgA vasculitis following COVID-19 vaccination. BMJ Case Rep. 2021;14: e247188.CrossRef Maye JA, Chong HP, Rajagopal V, Petchey W. Reactivation of IgA vasculitis following COVID-19 vaccination. BMJ Case Rep. 2021;14: e247188.CrossRef
14.
go back to reference Iwata H, Kamiya K, Kado S, Nakaya T, Kawata H, Komine M, Ohtsuki M. Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination. Dermatol. 2021;48:e598–9. Iwata H, Kamiya K, Kado S, Nakaya T, Kawata H, Komine M, Ohtsuki M. Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination. Dermatol. 2021;48:e598–9.
15.
go back to reference Nakatani S, Mori K, Morioka F, Hirata C, Tsuda A, Uedono H, Ishimura E, Tsuruta D, Emoto M. New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report. CEN Case Rep. 2022;25:1–5. Nakatani S, Mori K, Morioka F, Hirata C, Tsuda A, Uedono H, Ishimura E, Tsuruta D, Emoto M. New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report. CEN Case Rep. 2022;25:1–5.
16.
go back to reference Hashizume H, Ajima S, Ishikawa Y. Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases. J Dermatol. 2022;49:560–3.CrossRef Hashizume H, Ajima S, Ishikawa Y. Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases. J Dermatol. 2022;49:560–3.CrossRef
17.
go back to reference Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, Kano T, Suzuki Y. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93:700–5.CrossRef Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, Kano T, Suzuki Y. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93:700–5.CrossRef
18.
go back to reference Yamaji K, Suzuki Y, Suzuki H, Satake K, Horikoshi S, Novak J, Tomino Y. The kinetics of glomerular deposition of nephritogenic IgA. PLoS ONE. 2014;9: e113005.CrossRef Yamaji K, Suzuki Y, Suzuki H, Satake K, Horikoshi S, Novak J, Tomino Y. The kinetics of glomerular deposition of nephritogenic IgA. PLoS ONE. 2014;9: e113005.CrossRef
19.
go back to reference Hotta O, Ieiri N, Nagai M, Tanaka A, Harabuchi Y. Role of palatine tonsil and epipharyngeal lymphoid tissue in the development of glomerular active lesions (glomerular vasculitis) in immunoglobulin A nephropathy. Int J Mol Sci. 2022;23:727.CrossRef Hotta O, Ieiri N, Nagai M, Tanaka A, Harabuchi Y. Role of palatine tonsil and epipharyngeal lymphoid tissue in the development of glomerular active lesions (glomerular vasculitis) in immunoglobulin A nephropathy. Int J Mol Sci. 2022;23:727.CrossRef
20.
go back to reference Hana D, Patel K, Roman S, Gattas B, Sofka S. Clinical cardiovascular adverse events reported post-COVID-19 vaccination: are they a real risk? Curr Probl Cardiol. 2022;47: 101077.CrossRef Hana D, Patel K, Roman S, Gattas B, Sofka S. Clinical cardiovascular adverse events reported post-COVID-19 vaccination: are they a real risk? Curr Probl Cardiol. 2022;47: 101077.CrossRef
21.
go back to reference Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305–53.CrossRef Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305–53.CrossRef
22.
go back to reference Wang Y, Hsieh TC, Lee GY, Gorelick S, Maslak D. Ulcerative colitis flare-ups following mRNA COVID-19 vaccination. Am J Gastroenterology. 2021;116(SUPPL):S1029.CrossRef Wang Y, Hsieh TC, Lee GY, Gorelick S, Maslak D. Ulcerative colitis flare-ups following mRNA COVID-19 vaccination. Am J Gastroenterology. 2021;116(SUPPL):S1029.CrossRef
23.
go back to reference Mahler M, Bogdanos DP, Pavlidis P, Fritzler MJ, Csernok E, Dam Oiseaux J, Bentow C, Shums Z, Forbes A, Norman GL. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta. 2013;424:267–73.CrossRef Mahler M, Bogdanos DP, Pavlidis P, Fritzler MJ, Csernok E, Dam Oiseaux J, Bentow C, Shums Z, Forbes A, Norman GL. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta. 2013;424:267–73.CrossRef
24.
go back to reference Horn MP, Peter AM, Righini Grunder F, Leichtle AB, Spalinger J, Schibli S, Sokollik C. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn’s disease. PLoS ONE. 2018;13: e0208974.CrossRef Horn MP, Peter AM, Righini Grunder F, Leichtle AB, Spalinger J, Schibli S, Sokollik C. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn’s disease. PLoS ONE. 2018;13: e0208974.CrossRef
25.
go back to reference Chiarantini E, Valanzano R, Liotta AA, Cellai AP, Fedi S, Ilari I, Prisco D, Tonelli F, Abbate R. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res. 2019;82:137–46.CrossRef Chiarantini E, Valanzano R, Liotta AA, Cellai AP, Fedi S, Ilari I, Prisco D, Tonelli F, Abbate R. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res. 2019;82:137–46.CrossRef
26.
go back to reference Koutroubakis IE, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1998;43:2507–12.CrossRef Koutroubakis IE, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1998;43:2507–12.CrossRef
27.
go back to reference Talotta R, Robertson ES. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: the straw that breaks the camel’s back? Cytokine Growth Factor Rev. 2021;60:52–60.CrossRef Talotta R, Robertson ES. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: the straw that breaks the camel’s back? Cytokine Growth Factor Rev. 2021;60:52–60.CrossRef
28.
go back to reference Donadio ME, Loiacono E, Peruzzi L, Amore A, Camilla R, Chiale F, Vergano L, Boido A, Conrieri M, Bianciotto M, Bosetti FM, Coppo R. Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch-Schönlein purpura and primary IgA nephropathy. Pediatr Nephrol. 2014;29:1545–51.CrossRef Donadio ME, Loiacono E, Peruzzi L, Amore A, Camilla R, Chiale F, Vergano L, Boido A, Conrieri M, Bianciotto M, Bosetti FM, Coppo R. Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch-Schönlein purpura and primary IgA nephropathy. Pediatr Nephrol. 2014;29:1545–51.CrossRef
30.
go back to reference Dai W, Long L, Wang X, Li S, Xu H. Phytochemicals targeting Toll-like receptors 4 (TLR4) in inflammatory bowel disease. Chin Med. 2022;17:53.CrossRef Dai W, Long L, Wang X, Li S, Xu H. Phytochemicals targeting Toll-like receptors 4 (TLR4) in inflammatory bowel disease. Chin Med. 2022;17:53.CrossRef
Metadata
Title
IgA vasculitis with transient glomerular hematuria, diarrhea, and pericarditis following COVID-19 mRNA vaccination in a young patient with possible pre-existing ulcerative colitis
Authors
Chiaki Ito
Kohei Odajima
Yoshiko Niimura
Misako Fujii
Masayuki Sone
Shinichiro Asakawa
Shigeyuki Arai
Osamu Yamazaki
Yoshifuru Tamura
Koji Saito
Yayoi Tada
Takatsugu Yamamoto
Ken Kozuma
Shigeru Shibata
Yoshihide Fujigaki
Publication date
04-08-2022
Publisher
Springer Nature Singapore
Published in
CEN Case Reports / Issue 1/2023
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-022-00727-w

Other articles of this Issue 1/2023

CEN Case Reports 1/2023 Go to the issue